Bispecific antibodies (BsAbs) have changed the later-line treatment landscape for relapsed or refractory follicular lymphoma (FL). Increasingly, these agents are being studied for earlier lines of treatment, with a recent approval in the second-line setting. This article explores the evidence for, and ongoing trials of, early-line BsAb treatment for FL.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 1515 W Cypress Creek Rd
Pricing
100% of listed courses are free
56 of 56 courses listed here are free.
Collected from the provider’s public pages
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Board review / self-assessment
- Credit · Up to 0.5 credits
- MOC · Up to 0.5 points
- Commercial Support
-
ReleasedDec 22, 2025
-
Last day to claim creditFeb 28, 2027 5 months left
-
Clinical Care Options, LLC (dba Decera Clinical Education) Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions
-
PVI, PeerView Institute for Medical Education Pharmacist Leadership for Enhanced Lymphoma Care: Delivering Off-the-Shelf Efficacy With Bispecific Antibodies in DLBCL and FL
-
Medscape, LLC Global Insights on Bispecific Antibodies in Non-Hodgkin Lymphoma
